Wen Kai Xiang

Franklin Advisers, Inc. is a mutual fund manager and registered investment advisor headquartered in San Mateo, California. The firm was founded in 1985 and is a subsidiary of Franklin Resources, Inc. (NYSE: BEN), a holding company that, together with its various subsidiaries is referred to as Franklin Templeton Investments. Franklin Advisers provides investment advisory and portfolio management services to US and non-US, registered open-end and closed-end funds and unregistered funds, as well as separate accounts.

Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California.

The Biotechnology Greenhouse Corp. of Southeastern PA (BioAdvance) is a venture capital firm founded in 2002. The firm is headquartered in Philadelphia, Pennsylvania.

Genyous Biomed International, Inc. engages in the discovery, development, and manufacture of multifunctional multi targeted (MFMT) therapies to prevent, detect, and treat cancer and other chronic diseases. The firm offers MFMT therapies, which include anti-viral, anti-oxidative, anti-inflammatory, and immune modulating therapeutic effects for the treatment of solid tumors and related chronic diseases. The company was founded by Jeffrey Dao and James Dao in 2000 and is headquartered in and is headquartered in Henderson, NV.

Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.